SurroMed and Eunoe Collaborate to Improve Understanding of the Biochemical Basis of Alzheimer's Disease
Biological Markers Will Enable Earlier Diagnosis and Improved Therapeutics
Biological Markers Will Enable Earlier Diagnosis and Improved Therapeutics
MOUNTAIN VIEW and REDWOOD CITY, Calif., July 10 /PRNewswire/ -- SurroMed, Inc. and Eunoe, Inc. announced today an exclusive collaborative research agreement to study the biochemical basis of Alzheimer's disease. SurroMed will use its novel, integrated suite of technologies to analyze samples of cerebrospinal fluid (CSF) from Alzheimer's patients and obtained using Eunoe's COGNIShunt(R) device.
"The diagnosis of Alzheimer's disease relies heavily upon the subjective evaluation of the symptoms of dementia which are only apparent once the disease is already in an advanced stage," stated SurroMed CEO, Gordon Ringold, PhD. "By applying powerful analytical technologies to samples obtained directly from the site of disease, we hope to identify novel markers that could have utility for diagnosis and prognosis and could also lead to new therapeutic strategies."
"Eunoe's COGNIShunt has been designed based upon the hypothesis that CSF surrounding the brain is important in clearing toxic proteins thought to cause Alzheimer's disease," stated Eunoe's President, Dawn McGuire, MD. "This collaboration with SurroMed is a complementary step forward in the development of diagnostics and, ultimately, treatments for this terrible disease."
Under the terms of the agreement, SurroMed will analyze the samples with its novel, integrated comprehensive phenotyping platform, which incorporates proprietary, advanced bioanalytical technologies for cellular, proteomic and low-molecular-weight organic molecule profiling and analysis to identify biological markers of Alzheimer's disease. In addition to identifying markers that may have utility for disease diagnosis and monitoring, this research may also yield novel therapeutic targets. Eunoe will provide SurroMed with longitudinally derived ventricular fluid samples obtained from Alzheimer's patients participating in an ongoing Phase III clinical trial of Eunoe's COGNIShunt System, an implanted flow-controlled shunt for Alzheimer's disease treatment.
More than four million Americans are currently diagnosed with Alzheimer's disease, a progressive, degenerative disease that attacks the brain and results in impaired memory, thinking and behavior. According to the Alzheimer's Association, one in 10 people over 65 and nearly half of those over 85 have the disease. As the baby-boomer generation ages, the disease is becoming a growing health and social issue. Patients' families and communities are often affected by issues such as drained resources and requirements for around-the-clock care.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
About Eunoe, Inc.
Founded in 1995 (under the name CSFluids), Eunoe, Incorporated has developed a proprietary device-based treatment for Alzheimer's disease based on improving cerebrospinal fluid clearance of neurotoxic proteins associated with this dementia. A prospective, randomized pilot study of the COGNIShunt(R) conducted at three major medical centers has been completed, with encouraging results. An FDA-approved multicenter pivotal study is now underway.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Talya Gould
Account Coordinator
(415) 677-4455 ext. 284
email: [email protected]
Eunoe, Inc.
Dawn McGuire
President
(650) 216.1550
email: [email protected]
"The diagnosis of Alzheimer's disease relies heavily upon the subjective evaluation of the symptoms of dementia which are only apparent once the disease is already in an advanced stage," stated SurroMed CEO, Gordon Ringold, PhD. "By applying powerful analytical technologies to samples obtained directly from the site of disease, we hope to identify novel markers that could have utility for diagnosis and prognosis and could also lead to new therapeutic strategies."
"Eunoe's COGNIShunt has been designed based upon the hypothesis that CSF surrounding the brain is important in clearing toxic proteins thought to cause Alzheimer's disease," stated Eunoe's President, Dawn McGuire, MD. "This collaboration with SurroMed is a complementary step forward in the development of diagnostics and, ultimately, treatments for this terrible disease."
Under the terms of the agreement, SurroMed will analyze the samples with its novel, integrated comprehensive phenotyping platform, which incorporates proprietary, advanced bioanalytical technologies for cellular, proteomic and low-molecular-weight organic molecule profiling and analysis to identify biological markers of Alzheimer's disease. In addition to identifying markers that may have utility for disease diagnosis and monitoring, this research may also yield novel therapeutic targets. Eunoe will provide SurroMed with longitudinally derived ventricular fluid samples obtained from Alzheimer's patients participating in an ongoing Phase III clinical trial of Eunoe's COGNIShunt System, an implanted flow-controlled shunt for Alzheimer's disease treatment.
More than four million Americans are currently diagnosed with Alzheimer's disease, a progressive, degenerative disease that attacks the brain and results in impaired memory, thinking and behavior. According to the Alzheimer's Association, one in 10 people over 65 and nearly half of those over 85 have the disease. As the baby-boomer generation ages, the disease is becoming a growing health and social issue. Patients' families and communities are often affected by issues such as drained resources and requirements for around-the-clock care.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
About Eunoe, Inc.
Founded in 1995 (under the name CSFluids), Eunoe, Incorporated has developed a proprietary device-based treatment for Alzheimer's disease based on improving cerebrospinal fluid clearance of neurotoxic proteins associated with this dementia. A prospective, randomized pilot study of the COGNIShunt(R) conducted at three major medical centers has been completed, with encouraging results. An FDA-approved multicenter pivotal study is now underway.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Talya Gould
Account Coordinator
(415) 677-4455 ext. 284
email: [email protected]
Eunoe, Inc.
Dawn McGuire
President
(650) 216.1550
email: [email protected]